[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212 547 9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.", "fullTimeEmployees": 72, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend", "age": 43, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 864335, "exercisedValue": 0, "unexercisedValue": 6398299}, {"maxAge": 1, "name": "Dr. Eric  Adler M.D.", "age": 50, "title": "Chief Medical Officer & Head of Research", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 623400, "exercisedValue": 0, "unexercisedValue": 586874}, {"maxAge": 1, "name": "Ms. Jenny R. Robertson J.D.", "age": 49, "title": "Chief Legal Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 617900, "exercisedValue": 0, "unexercisedValue": 94692}, {"maxAge": 1, "name": "Dr. Ronald G. Crystal M.D.", "title": "Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kyle  Rasbach Ph.D., Pharm.D.", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jose Manuel Otero Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jordan M. Baumhardt Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 53, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  DiRisio", "title": "Senior Vice President of Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  McHenry", "title": "VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.64, "open": 2.53, "dayLow": 2.2668, "dayHigh": 2.66, "regularMarketPreviousClose": 2.64, "regularMarketOpen": 2.53, "regularMarketDayLow": 2.2668, "regularMarketDayHigh": 2.66, "payoutRatio": 0.0, "forwardPE": -0.8429603, "volume": 542667, "regularMarketVolume": 542667, "averageVolume": 518835, "averageVolume10days": 1333550, "averageDailyVolume10Day": 1333550, "bid": 2.3, "ask": 2.41, "bidSize": 4, "askSize": 4, "marketCap": 77515000, "fiftyTwoWeekLow": 2.2668, "fiftyTwoWeekHigh": 19.5, "fiftyDayAverage": 3.8387, "twoHundredDayAverage": 8.35525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -34079012, "profitMargins": 0.0, "floatShares": 21812751, "sharesOutstanding": 33197000, "sharesShort": 2215452, "sharesShortPriorMonth": 2310952, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.067, "heldPercentInsiders": 0.01249, "heldPercentInstitutions": 1.06055, "shortRatio": 4.47, "shortPercentOfFloat": 0.0749, "impliedSharesOutstanding": 33197000, "bookValue": 3.533, "priceToBook": 0.66091144, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -98333000, "trailingEps": -3.09, "forwardEps": -2.77, "enterpriseToEbitda": 0.324, "52WeekChange": -0.8225684, "SandP52WeekChange": -0.024663687, "quoteType": "EQUITY", "currentPrice": 2.335, "targetHighPrice": 28.0, "targetLowPrice": 16.0, "targetMeanPrice": 21.57143, "targetMedianPrice": 21.0, "recommendationMean": 1.42857, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 121518000, "totalCashPerShare": 3.661, "ebitda": -105137000, "totalDebt": 9924000, "quickRatio": 5.319, "currentRatio": 5.52, "debtToEquity": 8.494, "returnOnAssets": -0.46106, "returnOnEquity": -0.85366994, "grossProfits": -74091000, "freeCashflow": -48427376, "operatingCashflow": -81151000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "LXEO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Lexeo Therapeutics, Inc.", "longName": "Lexeo Therapeutics, Inc.", "marketState": "CLOSED", "priceEpsCurrentYear": -0.75517464, "fiftyDayAverageChange": -1.5037, "fiftyDayAverageChangePercent": -0.39172116, "twoHundredDayAverageChange": -6.0202503, "twoHundredDayAverageChangePercent": -0.720535, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-11-03", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "postMarketChangePercent": -1.07067, "postMarketPrice": 2.31, "postMarketChange": -0.0250001, "regularMarketChange": -0.30500007, "regularMarketDayRange": "2.2668 - 2.66", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 518835, "firstTradeDateMilliseconds": 1699018200000, "fiftyTwoWeekLowChange": 0.06820011, "fiftyTwoWeekLowChangePercent": 0.030086515, "fiftyTwoWeekRange": "2.2668 - 19.5", "fiftyTwoWeekHighChange": -17.165, "fiftyTwoWeekHighChangePercent": -0.8802565, "fiftyTwoWeekChangePercent": -82.25684, "epsTrailingTwelveMonths": -3.09, "epsForward": -2.77, "epsCurrentYear": -3.092, "regularMarketChangePercent": -11.553033, "regularMarketPrice": 2.335, "corporateActions": [], "postMarketTime": 1743798170, "regularMarketTime": 1743796802, "exchange": "NGM", "messageBoardId": "finmb_625814286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Lexeo Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-05"}]